Ribavirin
- Generic Name
- Ribavirin
- Brand Names
- Ibavyr, Rebetol, Virazole
- Drug Type
- Small Molecule
- Chemical Formula
- C8H12N4O5
- CAS Number
- 36791-04-5
- Unique Ingredient Identifier
- 49717AWG6K
- Background
Producing a broad-spectrum activity against several RNA and DNA viruses, Ribavirin is a synthetic guanosine nucleoside and antiviral agent that interferes with the synthesis of viral mRNA. It is primarily indicated for use in treating hepatitis C and viral hemorrhagic fevers. HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes...
- Indication
Indicated for the treatment of chronic Hepatitis C virus (HCV) infection in combination with other antiviral agents with the intent to cure or achieve a sustained virologic response (SVR). Typically added to improve SVR and reduce relapse rates .
...
- Associated Conditions
- Chronic Hepatitis C Virus (HCV) Infection, Severe Respiratory Syncytial Virus Infection
- Associated Therapies
- -
The Comparative Efficacy of Standard Treatment Plus Ribavirin vs Standard Treatment Alone in Preventing Clinically Significant Hemorrhage in Patients With Dengue Fever
- Conditions
- Interventions
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Khyber Medical University Peshawar
- Target Recruit Count
- 284
- Registration Number
- NCT06744777
- Locations
- 🇵🇰
Lady Reading Hospital, Peshawar, Khyber Pakhtunkhwa, Pakistan
🇵🇰Gandhara Medical Hospital, Peshawar, Khyber Pakhtunkhwa, Pakistan
🇵🇰Medical Complex Swabi, Swābi, Khyber Pakhtunkhwa, Pakistan
Assessing Antiviral Treatments in Early Symptomatic RSV
- Conditions
- Interventions
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 1000
- Registration Number
- NCT06488300
- Locations
- 🇹🇭
Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
LAssa Fever Adjunct Treatment With DEXamethasone
- First Posted Date
- 2024-01-25
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- Bernhard Nocht Institute for Tropical Medicine
- Target Recruit Count
- 42
- Registration Number
- NCT06222723
ISTH/ANRS 0409s INTEGRATE Lassa Fever Study
- Conditions
- Interventions
- First Posted Date
- 2024-01-18
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- Irrua Specialist Teaching Hospital
- Target Recruit Count
- 1755
- Registration Number
- NCT06212336
UMIT-1 Trial Favipiravir & Ribavirin for the Treatment of CCHF
- First Posted Date
- 2023-07-11
- Last Posted Date
- 2023-10-05
- Lead Sponsor
- Liverpool School of Tropical Medicine
- Target Recruit Count
- 24
- Registration Number
- NCT05940545
- Locations
- 🇹🇷
Ankara Oncology Training and Research Center, Ankara, Yenimahalle, Turkey
Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy
- Conditions
- Interventions
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT05717400
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Triple Combination Antiviral Coronavirus Therapy (TriACT) for COVID-19
- First Posted Date
- 2020-10-28
- Last Posted Date
- 2022-05-05
- Lead Sponsor
- Rutgers, The State University of New Jersey
- Target Recruit Count
- 7
- Registration Number
- NCT04605588
- Locations
- 🇺🇸
Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
IFN Beta-1b and Ribavirin for Covid-19
- First Posted Date
- 2020-07-31
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 96
- Registration Number
- NCT04494399
- Locations
- 🇭🇰
The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong
Treatment of Hemorrhagic Fever With Ribavirin
- First Posted Date
- 2020-02-25
- Last Posted Date
- 2022-07-22
- Target Recruit Count
- 50
- Registration Number
- NCT04283513
Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment
- Conditions
- Interventions
- First Posted Date
- 2020-02-19
- Last Posted Date
- 2020-04-15
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 127
- Registration Number
- NCT04276688
- Locations
- 🇭🇰
University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.